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Guidelines for antibiotic usage are among those public health conundrums with the highest stakes in 
modern medicine. Antibiotics remain our main treatment response against potentially fatal bacterial 
diseases, preventing millions of deaths every year, and there is emerging evidence for the benefits of 
preventative antibiotic administration. For example, pre-emptive azithromycin use in healthy 
children in regions with high child mortality can increase survival well beyond the capacity of the 
majority of other targeted interventions [1,2]. Conversely, there is compelling evidence that 
antibiotic use leads to increased antibiotic resistance prevalence in the community [3,4], an 
increasing proportion of no longer treatable multidrug resistant infections and eventually to a 
blunting of our antimicrobial arsenal [5,6]. Appropriate antibiotic use is thus a trade-off between 
medical best practice for improving patient outcomes and the wider public health implications of 
antibiotic use at the community level. Balancing this trade-off is particularly challenging in those 
instances where a substantial increase in antibiotic use in the community offers somewhat marginal 
health benefits; as is the case for the immediate treatment of otitis media if compared to a ‘reactive’ 
prescribing strategy triggered only by the worsening of symptoms [7]. Proposing an evidence-based 
solution to this issue requires understanding and quantifying the mechanisms underpinning 
transmission of bacterial carriage and the selection pressures governing the introduction and 
maintenance of non-susceptible strains. 
To elucidate these mechanisms, Lewnard et al. investigated the individual-level effect of antibiotic 
prescription on pneumococcal penicillin non-susceptible carriage [8]. In a secondary analysis of a 
randomised double-blind placebo-controlled trial, the authors studied the effects of immediate vs 
reactive amoxicillin-clavulanate prescription to children attending primary care for acute otitis media 
over a two-month follow-up period. As otitis media is the main reason for antibiotic prescribing in 
children in high income settings and contributes substantially to overall antibiotic use [9,10], 
understanding both the clinical impact and the selective pressure of antibiotic prescribing for otitis 
media is a key part in the optimisation of antibiotic prescription strategies. 
This reanalysis shows clear evidence that a strategy of immediate prescribing following diagnosis 
confers a fitness advantage on non-susceptible strains. Namely, that amoxicillin-clavulanate based 
treatment substantially reduces penicillin susceptible pneumococcal carriage prevalence but not 
that of its non-susceptible counterpart. The largest effect, an 88% reduction in susceptible carriage 
vs the placebo arm, was seen at the first follow up which was a week after enrolment and the end of 
the treatment course. Moreover, two months after enrolment, the prevalence of penicillin 
susceptible pneumococcal carriage in the treatment arm had rebounded but to a much lower level 
than it had been pre-treatment (52% vs 30%) and to a slightly lower level than in the control arm 
(41% vs 30%). Furthermore, the study provides evidence that that this fitness advantage is conferred 
by two mechanisms. First, treatment preferentially clears resident susceptible strains from the 
nasopharynx (7% vs 61% carriage prevalence immediately after treatment), with lower carriage 
prevalence of penicillin susceptible strains observed seven weeks after ending treatment (35% vs 
64%) . Second, treatment may actively block recolonisation by susceptible strains (2% vs 9% 
prevalence at end of treatment in participants uncolonized at enrolment)—possibly even during the 
days, or weeks, after the course is complete (2 vs 12% carriage prevalence one week after treatment 
has ended). These two mechanisms result in a vacated niche in the treatment arm, cleared of 
susceptible strains. 
One would expect that in the treated patients, the vacated niche would be filled, in part, by penicillin 
non-susceptible pneumococci, yet there was no evidence for this. While this finding is somewhat 
reassuring it is important to note that the study was only powered to detect roughly a doubling of 
penicillin non-susceptible pneumococcal carriage prevalence. For comparison, a prospective 
observational study in Malawi detected an increase in the prevalence of cotrimoxazole non-
susceptible pneumococci of about 20% in the weeks following treatment. However, mass 
administration of azithromycin in a cluster randomised trial led to almost a 5-fold increase in 
carriage of azithromycin resistant pneumococci compared with control clusters [5], hinting at a likely 
non-linear relationship between individual level and population level effects of antimicrobial 
resistance.  
The reanalysis elegantly highlights the complex carriage-treatment dynamics that underlie the 
deceptively simple linear relationship between antibiotic use and resistance across commensal 
bacteria–drug combinations that has been reported across Europe [3].  The explicit dynamics of 
increased antimicrobial use and a subsequent rise in resistance are poorly understood but are likely 
governed by a highly non-linear combination of factors with competition between susceptible and 
non-susceptible strains as the balancing mechanism at its core [11–13]. This gap in our knowledge 
implies that to date it remains impossible to adequately quantify the trade-off between the benefits 
of a specific antibiotic use recommendation and its implications for increased resistance and 
associated health losses. In particular, assessing population resistance levels may be complicated 
both by a delayed effect of changes in prescribing rates and by the uncertainty associated with 
inferring population level effects from individual level observations.  Although we are yet to fully 
grasp an intuitive and mechanistic understanding of this antibiotic use–resistance relationship [14–
16] it is clear that results such as those from Lewnard et al. will be essential to empirically 
parameterise the selective pressures on pneumococcal transmission.  Encouragingly, transmission 
models of resistant pathogens have routinely relied on calibrating their output using the two fitness 
advantages reported in by Lewnard et al. [12] and hence this study will help better equip future 
endeavours that aim to quantify the impact of competition on observed resistance levels.  
Ultimately, we have to work towards a mechanistic understanding of resistance transmission if our 
goal is to inform public health decision making for antibiotic use guidelines. With similar work on 
other bacteria-treatment combinations, we will build a comprehensive understanding of resistance 
acquisition and transmission across pathogens. Finally, we anticipate that strengthened evidence of 
antibiotic use–resistance relationships from countries outside Europe, especially those with higher 
antibiotic usage, will guide and corroborate our mechanistic understanding of resistance evolution. 
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